ParkinsonFranceV1, Main, Exploration, bibRecordById, pubmed:11176963

Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease

Identifieur interne : 003824 ( Main/Exploration ); précédent : 003823; suivant : 003825

Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease

Auteurs : O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis]

Source :

Archives of neurology : (Chicago) [ 0003-9942 ] ; 2001.

RBID : Pascal:01-0148533

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Stimulant dopaminergique, Récepteur dopaminergique D1, Chimiothérapie, Physiopathologie, Homme, Antiparkinsonien.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, D1 Dopamine receptor, Dopamine Agonists (administration & dosage), Dopamine agonist, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Dyskinesia, Drug-Induced, Female, Human, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson disease, Pathophysiology, Prodrugs (administration & dosage), Prodrugs (adverse effects), Pyridines (administration & dosage), Pyridines (adverse effects), Receptors, Dopamine D1 (drug effects), Tetrahydronaphthalenes (administration & dosage), Tetrahydronaphthalenes (adverse effects).
MESH :
- chemical , administration & dosage : Dopamine Agonists, Prodrugs, Pyridines, Tetrahydronaphthalenes.
- chemical , adverse effects : Prodrugs, Pyridines, Tetrahydronaphthalenes.
- chemical , drug effects : Receptors, Dopamine D1.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged.

Abstract

Background: Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D₁ and D₂ receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy. Objective: To establish whether a selective D₁ dopamine agonist induces more or less dyskinesia than levodopa in primed dyskinetic patients with Parkinson disease. Methods: We studied ABT-431, the prodrug of a fully selective D₁ agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. Eight patients were studied in a double-blind, randomized design (French centers); 12, in an open, randomized design (US centers). We assessed and compared the antiparkinsonian (Unified Parkinsons Disease Rating Scale) and dyskinetic (response induced by an acute challenge of a suprathreshold dose of levodopa and by 4 different ascending doses (5, 10, 20, and 40 mg) of ABT-431 during the 6 hours after the challenge. Results: The separate analysis of the double-blind and open data led to the same findings, ie, the antiparkinsonian and dyskinetic responses induced by ABT-431 were dose related. At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa. Conclusion: Dopamine D₁ agonists can induce a full antiparkinsonian response but do not support previous hypotheses suggesting that D₁ agonists are more or less likely to produce dyskinesias than levodopa.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Induction by Dopamine D<sub>1</sub>
 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Movement Disorders, Department of Neurological Sciences, Rush-Presbyterian-St Luke's Hospital</s1>
<s2>Chicago, Ill</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, Ill</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1>
<s2>Charlottesville</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1>
<s2>Charlottesville</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1>
<s2>Abbott Park, Ill</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Abbott Park, Ill</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1>
<s2>Abbott Park, Ill</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Abbott Park, Ill</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0148533</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0148533 INIST</idno>
<idno type="RBID">Pascal:01-0148533</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001251</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000187</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001060</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001060</idno>
<idno type="wicri:doubleKey">0003-9942:2001:Rascol O:induction:by:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003E16</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11176963</idno>
<idno type="wicri:Area/PubMed/Corpus">001260</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001260</idno>
<idno type="wicri:Area/PubMed/Curation">001219</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001219</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001219</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001219</idno>
<idno type="wicri:Area/Ncbi/Merge">000163</idno>
<idno type="wicri:Area/Ncbi/Curation">000163</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000163</idno>
<idno type="wicri:doubleKey">0003-9942:2001:Rascol O:induction:by:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003B40</idno>
<idno type="wicri:Area/Main/Curation">003824</idno>
<idno type="wicri:Area/Main/Exploration">003824</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Induction by Dopamine D<sub>1</sub>
 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Movement Disorders, Department of Neurological Sciences, Rush-Presbyterian-St Luke's Hospital</s1>
<s2>Chicago, Ill</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, Ill</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1>
<s2>Charlottesville</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1>
<s2>Charlottesville</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1>
<s2>Abbott Park, Ill</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Abbott Park, Ill</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1>
<s2>Abbott Park, Ill</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Abbott Park, Ill</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>D1 Dopamine receptor</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dopamine agonist</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Pathophysiology</term>
<term>Prodrugs (administration & dosage)</term>
<term>Prodrugs (adverse effects)</term>
<term>Pyridines (administration & dosage)</term>
<term>Pyridines (adverse effects)</term>
<term>Receptors, Dopamine D1 (drug effects)</term>
<term>Tetrahydronaphthalenes (administration & dosage)</term>
<term>Tetrahydronaphthalenes (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term>
<term>Prodrugs</term>
<term>Pyridines</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Prodrugs</term>
<term>Pyridines</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique D1</term>
<term>Chimiothérapie</term>
<term>Physiopathologie</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D<sub>1</sub>
 and D<sub>2</sub>
 receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy. Objective: To establish whether a selective D<sub>1</sub>
 dopamine agonist induces more or less dyskinesia than levodopa in primed dyskinetic patients with Parkinson disease. Methods: We studied ABT-431, the prodrug of a fully selective D<sub>1</sub>
 agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. Eight patients were studied in a double-blind, randomized design (French centers); 12, in an open, randomized design (US centers). We assessed and compared the antiparkinsonian (Unified Parkinsons Disease Rating Scale) and dyskinetic (response induced by an acute challenge of a suprathreshold dose of levodopa and by 4 different ascending doses (5, 10, 20, and 40 mg) of ABT-431 during the 6 hours after the challenge. Results: The separate analysis of the double-blind and open data led to the same findings, ie, the antiparkinsonian and dyskinetic responses induced by ABT-431 were dose related. At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa. Conclusion: Dopamine D<sub>1</sub>
 agonists can induce a full antiparkinsonian response but do not support previous hypotheses suggesting that D<sub>1</sub>
 agonists are more or less likely to produce dyskinesias than levodopa.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Oregon</li>
<li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Marseille</li>
<li>Portland</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
</region>
<name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name>
<name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name>
<name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
</country>
<country name="États-Unis"><region name="Oregon"><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name>
</region>
<name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name>
<name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name>
<name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name>
<name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name>
<name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003824 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003824 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:01-0148533
   |texte=   Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease

Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.